Characterization of the pharmacokinetics of a liposomal formulation of eribulin mesylate (E7389) in mice

International Journal of Pharmaceutics

Volumn 443, Issue 1-2, 2013, Pages 9-16

  Yu, Yanke ^a   Desjardins, Christopher ^a   Saxton, Phil ^a   Lai, George ^a   Schuck, Edgar ^a   Wong, Y Nancy ^a  

^a EISAI INC   (United States)

Author keywords

E7389; E7389 LF; Modeling; Pharmacokinetics; Sensitivity analysis; Ultracentrifugation

Indexed keywords

E 7389 LF; E 7389FL; ERIBULIN; LIPOSOME; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG FORMULATION; DRUG HALF LIFE; DRUG ISOLATION; DRUG RELEASE; DRUG STRUCTURE; LIQUID CHROMATOGRAPHY; MATHEMATICAL MODEL; MAXIMUM PLASMA CONCENTRATION; MODEL; MOUSE; NONHUMAN; PHARMACOKINETICS; PRIORITY JOURNAL; SINGLE DRUG DOSE; TANDEM MASS SPECTROMETRY; ULTRACENTRIFUGATION;

ANIMALS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG COMPOUNDING; DRUG STABILITY; FURANS; INJECTIONS, INTRAVENOUS; KETONES; LIMIT OF DETECTION; LIPOSOMES; MALE; MICE; MICE, INBRED STRAINS; MODELS, BIOLOGICAL; MOLECULAR STRUCTURE; TANDEM MASS SPECTROMETRY; TIME FACTORS; TUBULIN MODULATORS;

EID: 84873030031     PISSN: 03785173     EISSN: 18733476     Source Type: Journal    
DOI: 10.1016/j.ijpharm.2013.01.010     Document Type: Article

References (38)

1. P. Aftimos, and A. Awada Survival benefit of eribulin mesylate in heavily pretreated metastatic breast cancer: what next? Adv. Ther. 28 2011 973 985
2. A. Ahmad, Y.F. Wang, and I. Ahmad Separation of liposome-entrapped mitoxantrone from nonliposomal mitoxantrone in plasma: pharmacokinetics in mice Methods Enzymol. 391 2005 176 185
3. R. Bellott, P. Pouna, and J. Robert Separation and determination of liposomal and non-liposomal daunorubicin from the plasma of patients treated with Daunoxome J. Chromatogr. B: Biomed. Sci. Appl. 757 2001 257 267
4. J. Cortes, J. O'Shaughnessy, D. Loesch, J.L. Blum, L.T. Vahdat, K. Petrakova, P. Chollet, A. Manikas, V. Dieras, T. Delozier, V. Vladimirov, F. Cardoso, H. Koh, P. Bougnoux, C.E. Dutcus, S. Seegobin, D. Mir, N. Meneses, J. Wanders, and C. Twelves Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study Lancet 377 2011 914 923
5. D.Z. D'Argenio, A. Schumitzky, and X. Wang ADAPT5 User's Guide: Pharmacokinetic/Pharmacodynamic Systems Analysis Software 2009 Biomedical Simulations Resource Los Angeles
6. N.M. Deshpande, M.G. Gangrade, M.B. Kekare, and V.V. Vaidya Determination of free and liposomal amphotericin B in human plasma by liquid chromatography-mass spectroscopy with solid phase extraction and protein precipitation techniques J. Chromatogr. B: Analyt. Technol. Biomed. Life Sci. 878 2010 315 326
7. C. Desjardins, P. Saxton, S.X. Lu, X. Li, C. Rowbottom, and Y.N. Wong A high-performance liquid chromatography-tandem mass spectrometry method for the clinical combination study of carboplatin and anti-tumor agent eribulin mesylate (E7389) in human plasma J. Chromatogr. B: Analyt. Technol. Biomed. Life Sci. 875 2008 373 382
8. M. Donoghue, S.J. Lemery, W. Yuan, K. He, R. Sridhara, S. Shord, H. Zhao, A. Marathe, L. Kotch, J. Jee, Y. Wang, L. Zhou, W.M. Adams, V. Jarral, A. Pilaro, R. Lostritto, J.E. Gootenberg, P. Keegan, and R. Pazdur Eribulin mesylate for the treatment of patients with refractory metastatic breast cancer: use of a "physician's choice" control arm in a randomized approval trial Clin. Cancer Res. 18 2012 1496 1505
9. S. Druckmann, A. Gabizon, and Y. Barenholz Separation of liposome-associated doxorubicin from non-liposome-associated doxorubicin in human plasma: implications for pharmacokinetic studies Biochim. Biophys. Acta 980 1989 381 384
10. R. Fanciullino, and J. Ciccolini Liposome-encapsulated anticancer drugs: still waiting for the magic bullet? Curr. Med. Chem. 16 2009 4361 4371
11. FDA, 2010. FDA approves new treatment option for late-stage breast cancer. FDA News and Events, Washington, DC: FDA/Press announcemnets. Available from: http://www.dfa.gov/NewsEvents/Newsroom/PressAnnouncements/.
12. A. Gabizon, R. Catane, B. Uziely, B. Kaufman, T. Safra, R. Cohen, F. Martin, A. Huang, and Y. Barenholz Prolonged circulation time and enhanced accumulation in malignant exudates of doxorubicin encapsulated in polyethylene-glycol coated liposomes Cancer Res. 54 1994 987 992
13. A. Gabizon, H. Shmeeda, and Y. Barenholz Pharmacokinetics of pegylated liposomal Doxorubicin: review of animal and human studies Clin. Pharmacokinet. 42 2003 419 436
14. S. Goel, A.C. Mita, M. Mita, E.K. Rowinsky, Q.S. Chu, N. Wong, C. Desjardins, F. Fang, M. Jansen, D.E. Shuster, S. Mani, and C.H. Takimoto A phase I study of eribulin mesylate (E7389), a mechanistically novel inhibitor of microtubule dynamics, in patients with advanced solid malignancies Clin. Cancer Res. 15 2009 4207 4212
15. C. Gourmelon, J.S. Frenel, and M. Campone Eribulin mesylate for the treatment of late-stage breast cancer Expert Opin. Pharmacother. 12 2011 2883 2890
16. R.A. Hilger, H. Richly, M. Grubert, C. Oberhoff, D. Strumberg, M.E. Scheulen, and S. Seeber Pharmacokinetics (PK) of a liposomal encapsulated fraction containing doxorubicin and of doxorubicin released from the liposomal capsule after intravenous infusion of Caelyx/Doxil Int. J. Clin. Pharmacol. Ther. 43 2005 588 589
17. D.A. Hussar, and L. Pasco New drugs: ceftaroline fosamil, pegloticase, and eribulin mesylate J. Am. Pharm. Assoc. 51 2011 316 319
18. W. Jiang, R. Lionberger, and L.X. Yu In vitro and in vivo characterizations of PEGylated liposomal doxorubicin Bioanalysis 3 2011 333 344
19. M.A. Jordan, K. Kamath, T. Manna, T. Okouneva, H.P. Miller, C. Davis, B.A. Littlefield, and L. Wilson The primary antimitotic mechanism of action of the synthetic halichondrin E7389 is suppression of microtubule growth Mol. Cancer Ther. 4 2005 1086 1095
20. R.L. Juliano, and D. Stamp Pharmacokinetics of liposome-encapsulated anti-tumor drugs. Studies with vinblastine, actinomycin D, cytosine arabinoside, and daunomycin Biochem. Pharmacol. 27 1978 21 27
21. Kibuchi, H., Hyodo, K., Ishihara, H., 2012. Method of manufacture of liposome composition. United States Patent Application Publication.
22. C. Kirby, J. Clarke, and G. Gregoriadis Cholesterol content of small unilamellar liposomes controls phospholipid loss to high density lipoproteins in the presence of serum FEBS Lett. 111 1980 324 328
23. C. Kirby, J. Clarke, and G. Gregoriadis Effect of the cholesterol content of small unilamellar liposomes on their stability in vivo and in vitro Biochem. J. 186 1980 591 598
24. R. Krishna, M.S. Webb, G. St Onge, and L.D. Mayer Liposomal and nonliposomal drug pharmacokinetics after administration of liposome-encapsulated vincristine and their contribution to drug tissue distribution properties J. Pharmacol. Exp. Ther. 298 2001 1206 1212
25. D. Lawrence, P.R.C. Mayer, and B.Bally Marcel The use of transmembrane pH gradient-driven drug encapsulation in the pharmacodynamic evaluation of liposomal Doxorubicin J. Liposome Res. 4 1994 529 553
26. C. Li, C. Wang, H. Yang, X. Zhao, N. Wei, and J. Cui Liposomal topotecan formulation with a low polyethylene glycol grafting density: pharmacokinetics and antitumour activity J. Pharm. Pharmacol. 64 2012 372 382
27. L.D. Mayer, R. Nayar, R.L. Thies, N.L. Boman, P.R. Cullis, and M.B. Bally Identification of vesicle properties that enhance the antitumour activity of liposomal vincristine against murine L1210 leukemia Cancer Chemother. Pharmacol. 33 1993 17 24
28. L.D. Mayer, and G. St-Onge Determination of free and liposome-associated doxorubicin and vincristine levels in plasma under equilibrium conditions employing ultrafiltration techniques Anal. Biochem. 232 1995 149 157
29. L.D. Mayer, L.C. Tai, D.S. Ko, D. Masin, R.S. Ginsberg, P.R. Cullis, and M.B. Bally Influence of vesicle size, lipid composition, and drug-to-lipid ratio on the biological activity of liposomal doxorubicin in mice Cancer Res. 49 1989 5922 5930
30. T. Okouneva, O. Azarenko, L. Wilson, B.A. Littlefield, and M.A. Jordan Inhibition of centromere dynamics by eribulin (E7389) during mitotic metaphase Mol. Cancer Ther. 7 2008 2003 2011
31. H. Richly, M. Grubert, M.E. Scheulen, and R.A. Hilger Plasma and cellular pharmacokinetics of doxorubicin after intravenous infusion of Caelyx/Doxil in patients with hematological tumors Int. J. Clin. Pharmacol. Ther. 47 2009 55 57
32. G. Scherphof, F. Roerdink, M. Waite, and J. Parks Disintegration of phosphatidylcholine liposomes in plasma as a result of interaction with high-density lipoproteins Biochim. Biophys. Acta 542 1978 296 307
33. J.A. Smith, L. Wilson, O. Azarenko, X. Zhu, B.M. Lewis, B.A. Littlefield, and M.A. Jordan Eribulin binds at microtubule ends to a single site on tubulin to suppress dynamic instability Biochemistry 49 2010 1331 1337
34. A.R. Tan, E.H. Rubin, D.C. Walton, D.E. Shuster, Y.N. Wong, F. Fang, S. Ashworth, and L.S. Rosen Phase I study of eribulin mesylate administered once every 21 days in patients with advanced solid tumors Clin. Cancer Res. 15 2009 4213 4219
35. R.L. Thies, D.W. Cowens, P.R. Cullis, M.B. Bally, and L.D. Mayer Method for rapid separation of liposome-associated doxorubicin from free doxorubicin in plasma Anal. Biochem. 188 1990 65 71
36. E. Yamamoto, K. Hyodo, N. Ohnishi, T. Suzuki, H. Ishihara, H. Kikuchi, and N. Asakawa Direct, simultaneous measurement of liposome-encapsulated and released drugs in plasma by on-line SPE-SPE-HPLC J. Chromatogr. B: Analyt. Technol. Biomed. Life Sci. 879 2011 3620 3625
37. Y. Yu, L. Fang, and D. Sun Biodistribution of HuCC49DeltaCH2-beta- galactosidase in colorectal cancer xenograft model Int. J. Pharm. 386 2010 208 215
38. L. Zhang, F.X. Gu, J.M. Chan, A.Z. Wang, R.S. Langer, and O.C. Farokhzad Nanoparticles in medicine: therapeutic applications and developments Clin. Pharmacol. Ther. 83 2008 761 769